#STOLENCOLON REPLACEMENTS MAKE THEIR DEBUT IN KANSAS CITY AND NEW YORK CITY

by NASDAQ Market News February 28, 2019

NASDAQ Market News
Click here to email author

Abpro and NJCTTQ Enter Into Partnership for Development of Multiple Novel Bispecific Antibodies

RECORDATI: BOARD APPROVES THE 2018 ACCOUNTS. SALES € 1,352.2 MILLION (+5.0%), EBITDA € 499.1 MILLION (+9.8%), OPERATING INCOME € 442.2 MILLION (+8.8%) AND NET INCOME € 312.4 MILLION (+8.2%). 2018 DIVIDEND € 0.92 (+8.2%)

Ads